3649 results for «466»

Filter By

3649 results

The Physiology Course - Introduction

18 May 2026 – From EuroPCR 2026

The Physiology Course introduction welcomes participants and provides an overview of the importance of coronary physiology, outlining the program designed in collaboration with EuroPCR.

The physiological mindset: foundations every modern operator must own

18 May 2026 – From EuroPCR 2026

This session delves into the fundamental principles governing coronary blood flow regulation, emphasizing coronary autoregulation and the influence of epicardial haemodynamics on vascular morphology. Participants deepen their understanding of coronary physiology beyond formulas, exploring the intersection of physiology and atherosclerosis.

Physiology in the real world: how to measure, when to trust it, what to do?

18 May 2026 – From EuroPCR 2026

This session provides comprehensive insights into coronary physiology assessment tools, emphasizing techniques for reliable haemodynamic measurements and exploring clinical considerations surrounding coronary spasms and myocardial bridges.

Rapid fire session on next generation structural heart and valve therapies

18 May 2026 – From EuroPCR 2026

An intensive rapid-fire session presenting the latest advancements in next-generation structural heart and valve therapies, including novel transcatheter systems for aortic and mitral valve repair, innovative solutions for tricuspid regurgitation, and implant-free PFO closure technologies.

RESHAPE-HF2 - Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure

01 Sep 2024

Nicola Ryan provides her take on the RESHAPE-HF2 trial presented by Stefan Anker at the ESC Congress 2024 in London and simultaneously published in the NEJM.

The RESHAPE-HF 2 trial is a prospective randomised control trial comparing transcatheter mitral valve repair (TEER) and guideline-directed medical therapy to guideline-directed medical...

Nicola Ryan

Author

Nicola Ryan
RESHAPE-HF2

Frequency and safety of bioprosthetic valve fracture in patients undergoing valve in valve TAVR for failed surgical valves using the SAPIEN 3/Ultra Valves: Insights from real-world data

19 Sep 2022

Michele Pighi provides his take on this trial which aimed to compare the safety and efficacy of VIV-TAVI with or without bioprosthetic valve fracture. It was presented by Santiago Garcia during the TCT Congress 2022.

M. Pighi

Author

Michele Pighi
Bioprosthetic valve fracture in ViV-TAVR

The FLAVOUR Randomized Clinical Trial: Comparison of Fractional Flow Reserve-guided and Intravascular Ultrasound-guided Percutaneous Coronary Intervention in Intermediate Coronary Artery Stenosis

22 Mar 2022

Daniele Giacoppo analyses the main results of the FLAVOUR trial which were presented by Bon-Kwon Koo, from Seoul National University Hospital, South Korea at the American College of Cardiology 2022. 

Daniele Giacoppo

Author

Daniele Giacoppo
The FLAVOUR Randomized Clinical Trial: Comparison of Fractional Flow Reserve-guided and Intravascular Ultrasound-guided Percutaneous Coronary Intervention in Intermediate Coronary Artery Stenosis

Transcatheter aortic valve implantation without routine percutaneous coronary intervention: A randomized controlled trial (PRO-TAVI Trial)

29 Mar 2026

Jonathan Curio provides his take on the PRO-TAVI trial presented by Michiel Voskuil at ACC.26 in New Orleans and simultaneously published in The Lancet.

Jonathan Curio

Author

Jonathan Curio
TAVI without routine PCI: PRO-TAVI randomized controlled trial

Aortic stenosis and coronary artery disease: which should be treated first?

18 Jun 2026

In this review, Henryk Dreger explores the complex interplay between aortic stenosis and coronary artery disease, highlighting the latest evidence on PCI timing and its implications for clinical decision-making.

Henryk Dreger

Author

Henryk Dreger
Aortic stenosis and coronary artery disease: which should be treated first?
Didn’t find what you were looking for?